U.S. advisers shoot down semuloparin for cancer patients
15:20 EDT 20 Jun 2012 | Advanstar News Headlines
SILVER SPRING, Md. (Reuters) - French drugmaker Sanofi SA failed to win a U.S. panel's support on Wednesday for their experimental antithrombotic semuloparin to prevent blood clots in certain cancer patients, making it unlikely the drug would..
Original Article: U.S. advisers shoot down semuloparin for cancer patients
More From BioPortfolio on "U.S. advisers shoot down semuloparin for cancer patients"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
